SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-020873
Filing Date
2023-05-11
Accepted
2023-05-11 08:46:14
Documents
79
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20230331.htm   iXBRL 10-Q 2643446
2 EX-31.1 cadl-ex31_1.htm EX-31 19696
3 EX-31.2 cadl-ex31_2.htm EX-31 19393
4 EX-32.1 cadl-ex32_1.htm EX-32 10893
5 EX-32.2 cadl-ex32_2.htm EX-32 11438
  Complete submission text file 0000950170-23-020873.txt   9252433

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cadl-20230331_cal.xml EX-101.CAL 41745
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20230331.xsd EX-101.SCH 68666
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20230331_lab.xml EX-101.LAB 537581
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cadl-20230331_def.xml EX-101.DEF 292742
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20230331_pre.xml EX-101.PRE 418971
73 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20230331_htm.xml XML 1456830
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 23909057
SIC: 2836 Biological Products, (No Diagnostic Substances)